Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of ESCC is gradually increasing. Camrelizumab is one such immune checkpoint inhibitor (ICI) used for treatment. In this retrospective st...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Yujin, Zhao, Cong, Li, Xiangnan, Zhao, Jia, Huang, Qi, Ding, Zheng, Zhang, Yan, Jiao, Jia, Zhang, Guoqing, Zhao, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329664/
https://www.ncbi.nlm.nih.gov/pubmed/35911723
http://dx.doi.org/10.3389/fimmu.2022.953229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329664/
https://www.ncbi.nlm.nih.gov/pubmed/35911723
http://dx.doi.org/10.3389/fimmu.2022.953229

Ejemplares similares